10x Genomics Q1 Revenue Beats Estimates, Net Loss Narrows on Cost Cuts
summarizeSummary
10x Genomics reported Q1 revenue of $150.8 million, which, despite a 3% year-over-year fall, significantly beat analyst estimates of $146.36 million. The company also narrowed its net loss to $13.5 million from $34.4 million a year ago, improved gross margin to 70%, and reduced operating expenses by 15%. This news follows an 8-K filing earlier today that highlighted the reduced Q1 operating and net losses and the launch of the new Atera platform. This Reuters report provides the crucial detail of the revenue beat against expectations, complementing the earlier filing. Beating revenue estimates and showing significant improvements in profitability metrics (narrowed loss, improved gross margin, reduced expenses) are strong positive signals for investors, indicating better-than-expected operational execution. Maintaining full-year revenue guidance further reinforces stability. Investors will monitor the rollout and adoption of the new Atera platform in the second half of 2026, as well as continued progress on cost management and profitability.
At the time of this announcement, TXG was trading at $21.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $7.72 to $26.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.